Skip to main content

UTILIDAD TERAPEUTICA Y DE NUEVOS TRATAMIENTOS PARA LAS ENFERMEDADES HEPATICAS: RNA DE INTERFERENCIA PARA PTTG1, NANOPARTICULAS DE CARBONO GRAFITO Y DONADORES DE OXIDO NITRICO

RTI2018-094734-B-C21

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease

  • Carvajal, Silvia
  • Perramón, Meritxell
  • Oró, Denise
  • Casals, Eudald
  • Fernández-Varo, Guillermo
  • Casals, Gregori
  • Parra-Robert, Marina
  • González de la Presa, Bernardino
  • Ribera, Jordi
  • Pastor, Óscar
  • Morales-Ruiz, Manuel
  • Puntes, Víctor F.
  • Jiménez, Wladimiro
Some findings of these studies were previously presented at The International Liver Congress (ILC) 2017 Meeting of the European Association for the Study of the Liver (EASL) (19–23 April, 2017; Amsterdam, The Netherlands)., Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new antioxidant agent with hepatoprotective properties in experimental liver disease. The aim of the current investigation was to elucidate whether CeO2NPs display beneficial effects in an experimental model of NAFLD.Therefore, fifteen Wistar rats were subjected to a methionine and choline deficient diet (MCDD) for 6 weeks and intravenously treated with CeO2NP or vehicle during the weeks three and four of the diet. The effect of CeO2NPs on serum biochemistry, hepatic steatosis, inflammation, fatty acid content and expression of reactive oxygen species (ROS) and lipid metabolism related genes was assessed. MCDD fed rats showed increased inflammation, enhanced hepatic lipid accumulation of both saturated and unsaturated fatty acids (FAs) and overexpression of genes related to fatty liver and ROS metabolism. Treatment with CeO2NPs was able to reduce the size and content of hepatocyte lipid droplets, the hepatic concentration of triglyceride- and cholesterol ester-derived FAs and the expression of several genes involved in cytokine, adipokine and chemokine signaling pathways. These findings suggest that CeO2NPs could be of beneficial value in NAFLD., This research was supported by grants to W. Jiménez from Ministerio de Economia y Competitividad [grants SAF2015-64126R, 12-35979, BES-2013-063685, SAFRTI2018-094734-B-C21], to M. Morales-Ruiz [grant SAF2016-75358-R] and to G. Casals [grant P74844I/15/00777]; Cofinanced by FEDER, European Union, a way of making Europe, Agència de Gestió d’Ajuts Universitaris i de Recerca [grant SGR 2014/219]. The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles protect against oxidant injury and interfere with oxidative mediated kinase signaling in human-derived hepatocytes

  • Carvajal, Silvia
  • Perramón, Meritxell
  • Casals, Gregori
  • Oró, Denise
  • Ribera, Jordi
  • Morales-Ruiz, Manuel
  • Casals, Eudald
  • Casado, Pedro
  • Melgar-Lesmes, Pedro
  • Fernández-Varo, Guillermo
  • Cutillas, Pedro
  • Puntes, Víctor F.
  • Jiménez, Wladimiro
This article belongs to the Special Issue Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH)., Cerium oxide nanoparticles (CeO2NPs) possess powerful antioxidant properties, thus emerging as a potential therapeutic tool in non-alcoholic fatty liver disease (NAFLD) progression, which is characterized by a high presence of reactive oxygen species (ROS). The aim of this study was to elucidate whether CeO2NPs can prevent or attenuate oxidant injury in the hepatic human cell line HepG2 and to investigate the mechanisms involved in this phenomenon. The effect of CeO2NPs on cell viability and ROS scavenging was determined, the differential expression of pro-inflammatory and oxidative stress-related genes was analyzed, and a proteomic analysis was performed to assess the impact of CeO2NPs on cell phosphorylation in human hepatic cells under oxidative stress conditions. CeO2NPs did not modify HepG2 cell viability in basal conditions but reduced H2O2- and lipopolysaccharide (LPS)-induced cell death and prevented H2O2-induced overexpression of MPO, PTGS1 and iNOS. Phosphoproteomic analysis showed that CeO2NPs reverted the H2O2-mediated increase in the phosphorylation of peptides related to cellular proliferation, stress response, and gene transcription regulation, and interfered with H2O2 effects on mTOR, MAPK/ERK, CK2A1 and PKACA signaling pathways. In conclusion, CeO2NPs protect HepG2 cells from cell-induced oxidative damage, reducing ROS generation and inflammatory gene expression as well as regulation of kinase-driven cell survival pathways., This research was funded by grants to W. Jiménez from Ministerio de Economia y Competitividad [grants, SAF2015-64126-R, RTI2018-094734-B-C21], to M. Morales-Ruiz [grant SAF2016-75358-R] and to G. Casals [grant PI-15/00777]; cofinanced by FEDER, European Union, a way of making Europe, Agència de Gestió d’Ajuts Universitaris i de Recerca [grant SGR 2014/219]; and Fundació La Marató de TV3 [grant Marató 120930];Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 and Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to Eudald Casals The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles: Advances in biodistribution, toxicity, and preclinical exploration

  • Casals, Eudald
  • Zeng, Muling
  • Parra-Robert, Marina
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Jiménez, Wladimiro
  • Puntes, Víctor F.
  • Casals, Gregori
Antioxidant nanoparticles have recently gained tremendous attention for their enormous potential in biomedicine. However, discrepant reports of either medical benefits or toxicity, and lack of reproducibility of many studies, generate uncertainties delaying their effective implementation. Herein, the case of cerium oxide is considered, a well‐known catalyst in the petrochemistry industry and one of the first antioxidant nanoparticles proposed for medicine. Like other nanoparticles, it is now described as a promising therapeutic alternative, now as threatening to health. Sources of these discrepancies and how this analysis helps to overcome contradictions found for other nanoparticles are summarized and discussed. For the context of this analysis, what has been reported in the liver is reviewed, where many diseases are related to oxidative stress. Since well‐dispersed nanoparticles passively accumulate in liver, it represents a major testing field for the study of new nanomedicines and their clinical translation. Even more, many contradictory works have reported in liver either cerium‐oxide‐associated toxicity or protection against oxidative stress and inflammation. Based on this, finally, the intention is to propose solutions to design improved nanoparticles that will work more precisely in medicine and safely in society., This research was funded by Ministerio de Economía y Competitividad, grants numbers PI15/00077 and PI19/00774 to G.C. and G.F.‐V.; Direccion General de Investigacion Cientifica y Técnica SAF 15‐64126 and RTI2018‐094734‐B‐C21 to W.J and SAF2016‐75358‐R to M.M‐R., cofinanced by FEDER, European Union, “A way of making Europe;” “Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya, convocatòria d'Indústria del Coneixement modalitat B,” grant number 2018_PROD_00187 to W.J., cofinanced by the European Union through the European Regional Development Fund (ERDF), “A way of making Europe;” CIBERehd is financed by the Instituto de Salud Carlos III; Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C. and 2018TP011 to M.Z.; Foundation from Department of Education of Guangdong Province, grant numbers 2016KCXTD005 and 2017KSYS010, to E.C. and M.Z.; National Natural Science Foundation of China (NFSC), grant number: 31950410536 to E.C., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bespoken nanoceria: An effective treatment in experimental hepatocellular carcinoma

  • Fernández-Varo, Guillermo
  • Perramón, Meritxell
  • Carvajal, Silvia
  • Oró, Denise
  • Casals, Eudald
  • Boix, Loreto
  • Oller, Laura
  • Macías‐Muñoz, Laura
  • Marfà, Santi
  • Casals, Gregori
  • Morales-Ruiz, Manuel
  • Casado, Pedro
  • Cutillas, Pedro
  • Bruix, Jordi
  • Navasa, Miquel
  • Fuster, Josep
  • García-Valdecasas, Juan Carlos
  • Pavel, Mihai C.
  • Puntes, Víctor F.
  • Jiménez, Wladimiro
[Background and Aims]: Despite the availability of new‐generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer‐related deaths worldwide. Cerium oxide nanoparticles (CeO2NPs) have emerged as an antioxidant agent in experimental liver disease because of their antioxidant, anti‐inflammatory, and antisteatotic properties. In the present study, we aimed to elucidate the potential of CeO2NPs as therapeutic agents in HCC., [Approach and Results]: HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO2NPs at weeks 16 and 17. At the eighteenth week, nanoceria biodistribution was assessed by mass spectrometry (MS). The effect of CeO2NPs on tumor progression and animal survival was investigated. Hepatic tissue MS‐based phosphoproteomics as well as analysis of principal lipid components were performed. The intracellular uptake of CeO2NPs by human ex vivo perfused livers and human hepatocytes was analyzed. Nanoceria was mainly accumulated in the liver, where it reduced macrophage infiltration and inflammatory gene expression. Nanoceria treatment increased liver apoptotic activity, while proliferation was attenuated. Phosphoproteomic analysis revealed that CeO2NPs affected the phosphorylation of proteins mainly related to cell adhesion and RNA splicing. CeO2NPs decreased phosphatidylcholine‐derived arachidonic acid and reverted the HCC‐induced increase of linoleic acid in several lipid components. Furthermore, CeO2NPs reduced serum alpha‐protein levels and improved the survival of HCC rats. Nanoceria uptake by ex vivo perfused human livers and in vitro human hepatocytes was also demonstrated., [Conclusions]: These data indicate that CeO2NPs partially revert the cellular mechanisms involved in tumor progression and significantly increase survival in HCC rats, suggesting that they could be effective in patients with HCC., Supported by Dirección General de Investigación Científica y Técnica, Ministerio de Ciencia, Innovación y Universidades (SAF15‐64126‐R and RTI2018‐094734‐B‐C21, to W.J.; SAF2016‐75358‐R, to M.M.‐R.), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019, to W.J.), Instituto de Salud Carlos III (FIS PI15‐00077 and FIS PI19‐00774, to G.C. and G.F.‐V.; PI18/00763, to J.B. and L.B.), AECC (PI044031, to J.B. and L.B.), and WCR (AICR) (16‐0026, to J.B. and L.B.). Co‐funded by European Regional Development Fund/ European Social Fund (ERDF/ESF) "A way to make Europe"/ "Investing in your future". Cofinanced by Agència de Gestió d’Ajuts Universitaris i de Recerca and ERDF/ESF "A way to make Europe"/ "Investing in your future" under the Operational Program of Catalonia 2014‐2020 (grant 2018 PROD 00187). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles: A new therapeutic tool in liver diseases

  • Casals, Gregori
  • Perramón, Meritxell
  • Casals, Eudald
  • Portolés, Irene
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Puntes, Víctor F.
  • Jiménez, Wladimiro
Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well., Researches referred by the authors were funded by Fundació La Marató de TV3 (grant Marató 120930), Dirección General de Investigación Científica y Técnica (SAF15-64126-R and RTI2018-094734-B-C21, PID2019-105502RB, and BES-2017-08023), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019), and Instituto de Salud Carlos III (FIS PI15-00077 and FIS PI19-00774) co-financed by FEDER, European Union, “A way of making Europe” and the National Natural Science Foundation of China (31950410536). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration

  • Ernst, Lena M.
  • Mondragón, Laura
  • Ramis, Joana
  • Gusta, Muriel F.
  • Yudina, Tetyana
  • Casals, Eudald
  • Bastús, Neus G.
  • Fernández-Varo, Guillermo
  • Casals, Gregori
  • Jiménez, Wladimiro
  • Puntes, Víctor F.
Nanoparticle (NP) pharmacokinetics significantly differ from traditional small molecule principles. From this emerges the need to create new tools and concepts to harness their full potential and avoid unnecessary risks. Nanoparticle pharmacokinetics strongly depend on size, shape, surface functionalisation, and aggregation state, influencing their biodistribution, accumulation, transformations, and excretion profile, and hence their efficacy and safety. Today, while NP biodistribution and nanoceria biodistribution have been studied often at short times, their long-term accumulation and excretion have rarely been studied. In this work, 3 nm nanoceria at 5.7 mg/kg of body weight was intravenously administrated in a single dose to healthy mice. Biodistribution was measured in the liver, spleen, kidney, lung, brain, lymph nodes, ovary, bone marrow, urine, and faeces at different time points (1, 9, 30, and 100 days). Biodistribution and urinary and faecal excretion were also studied in rats placed in metabolic cages at shorter times. The similarity of results of different NPs in different models is shown as the heterogeneous nanoceria distribution in organs. After the expectable accumulation in the liver and spleen, the concentration of cerium decays exponentially, accounting for about a 50% excretion of cerium from the body in 100 days. Cerium ions, coming from NP dissolution, are most likely excreted via the urinary tract, and ceria nanoparticles accumulated in the liver are most likely excreted via the hepatobiliary route. In addition, nanoceria looks safe and does not damage the target organs. No weight loss or apathy was observed during the course of the experiments., This research was obtained the financial support from the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU) (RTI2018-099965-B-I00, AEI/FEDER, UE) proyectos de I + D + I de programación conjunta internacional MCIN/AEI (CONCORD, PCI2019-103436) co-funded by the European Union and Generalitat de Catalunya (2017-SGR-1431). ICN2 is supported by the Severo Ochoa program from Spanish MINECO (SEV-2017-0706) and is funded by the CERCA Programme/Generalitat de Catalunya. L.M. thanks the financial support from AGAUR by means of the Grants for the incorporation of post-doctoral research staff into the Catalan science and technology system within the Beatriu de Pinós program (Grant No. 2016 BP 00350) and MICINN through the Ramón y Cajal program (RYC2019-026522-I). We would like to thank the Chemical Analysis Service at Autonomous University of Barcelona (SAQs, UAB, Barcelona, Spain) for the Ce content analysis developed. We acknowledge financial support from Dirección General de Investigación Científica y Técnica (Ministerio de Ciencia, Innovación y Universidades (RTI2018-094734-B-C21, to W. Jiménez), and Insituto de Salut Carlos III (FIS PI19-00774, to G. Casals and G. fernández-Varo)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans

  • Córdoba-Jover, Bernat
  • Ribera, Jordi
  • Portolés, Irene
  • Lecue, Elena
  • Rodriguez-Vita, Juan
  • Pérez-Sisqués, Leticia
  • Mannara, Francesco
  • Solsona-Vilarrasa, Estel
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Casals, Gregori
  • Rodríguez-Revenga, Laia
  • Álvarez-Mora, María Isabel
  • Arteche-López, Ana
  • Díaz de Bustamante, Aranzazu
  • Calvo, Rosa
  • Pujol, Anna
  • Azkargorta, Mikel
  • Elortza, Felix
  • Malagelada, Cristina
  • Pinyol, Roser
  • Huguet-Pradell, Júlia
  • Melgar-Lesmes, Pedro
  • Jiménez, Wladimiro
  • Morales-Ruiz, Manuel
Transcription co-activator factor 20 (TCF20) is a regulator of transcription factors involved in extracellular matrix remodelling. In addition, TCF20 genomic variants in humans have been associated with impaired intellectual disability. Therefore, we hypothesized that TCF20 has several functions beyond those described in neurogenesis, including the regulation of fibrogenesis., We acknowledge the support from grants PDI2019-105502RB-100 and PID2022-138243OB-I00 to MM-R, PID2019-111669RB, BES-2017-080823 to IP "ESF Investing in your future", and RTI2018-094734-B-C21 to WJ and PM-L, from MCIN/AEI/10.13039/501100011033. RedFibro (RED2022-134485-T) of the 2022 caLL for aid to «RESEARCH NETWORKS», within the framework of the Programa Estatal del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021–2023. Consolidated Research Group of the Generalitat de Catalunya AGAUR (2021 SGR 00881 to MM-R) and PM-L financed ESF Investing in your future, support from AGAUR of the Generalitat de Catalunya. Fundación Mutua Madrileña AP171442019, European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, and the Project 201 916/31 Contribution of mitochondrialoxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3. PM-L was additionally supported by a fellowship from the Ramon y Cajal Program (RYC2018-0Z23971-I) and a grant (PID2021-123426OB-I00) from the Spanish Ministerio de Ciencia, Innovación y Universidades. CIBERehd is financed by the Instituto de Salud Carlos III., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes

  • Carvajal, Silvia
  • Perramón, Meritxell
  • Casals, Gregori
  • Oró, Denise
  • Ribera, Jordi
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
Nanopartícules d’òxid de ceri; Cèl·lules hepàtiques humanes; Fosfoproteòmica, Nanopartículas de óxido de cerio; Células hepáticas humanas; Fosfoproteómica, Cerium oxide nanoparticles; Human hepatic cells; Phosphoproteomics, Cerium oxide nanoparticles (CeO2NPs) possess powerful antioxidant properties, thus emerging as a potential therapeutic tool in non-alcoholic fatty liver disease (NAFLD) progression, which is characterized by a high presence of reactive oxygen species (ROS). The aim of this study was to elucidate whether CeO2NPs can prevent or attenuate oxidant injury in the hepatic human cell line HepG2 and to investigate the mechanisms involved in this phenomenon. The effect of CeO2NPs on cell viability and ROS scavenging was determined, the differential expression of pro-inflammatory and oxidative stress-related genes was analyzed, and a proteomic analysis was performed to assess the impact of CeO2NPs on cell phosphorylation in human hepatic cells under oxidative stress conditions. CeO2NPs did not modify HepG2 cell viability in basal conditions but reduced H2O2- and lipopolysaccharide (LPS)-induced cell death and prevented H2O2-induced overexpression of MPO, PTGS1 and iNOS. Phosphoproteomic analysis showed that CeO2NPs reverted the H2O2-mediated increase in the phosphorylation of peptides related to cellular proliferation, stress response, and gene transcription regulation, and interfered with H2O2 effects on mTOR, MAPK/ERK, CK2A1 and PKACA signaling pathways. In conclusion, CeO2NPs protect HepG2 cells from cell-induced oxidative damage, reducing ROS generation and inflammatory gene expression as well as regulation of kinase-driven cell survival pathways., This research was funded by grants to W. Jiménez from Ministerio de Economia y Competitividad [grants, SAF2015-64126-R, RTI2018-094734-B-C21], to M. Morales-Ruiz [grant SAF2016-75358-R] and to G. Casals [grant PI-15/00777]; cofinanced by FEDER, European Union, a way of making Europe, Agència de Gestió d’Ajuts Universitaris i de Recerca [grant SGR 2014/219]; and Fundació La Marató de TV3 [grant Marató 120930]; Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 and Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to Eudald Casals The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases

  • Casals, Gregori
  • Perramón, Meritxell
  • Portolés, Irene
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
  • Casals, Eudald
Carcinoma hepatocel·lular; Regeneració hepàtica; Nanocèria, Carcinoma hepatocelular; Regeneración hepática; Nanoceria, Hepatocellular carcinoma; Liver regeneration; Nanoceria, Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO2NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO2NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO2NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well., Researches referred by the authors were funded by Fundació La Marató de TV3 (grant Marató 120930), Dirección General de Investigación Científica y Técnica (SAF15-64126-R and RTI2018-094734-B-C21, PID2019-105502RB, and BES-2017-08023), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019), and Instituto de Salud Carlos III (FIS PI15-00077 and FIS PI19-00774) co-financed by FEDER, European Union, “A way of making Europe” and the National Natural Science Foundation of China (31950410536). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles protect against oxidant injury and interfere with oxidative mediated kinase signaling in human-derived hepatocytes

  • Carvajal, Silvia
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Casals, Gregori|||0000-0002-3271-1371
  • Oró, Denise
  • Ribera, Jordi|||0000-0002-0288-4220
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Casals, Eudald|||0000-0002-2900-7295
  • Casado, Pedro|||0000-0002-4207-9349
  • Melgar Lesmes, Pedro
  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Cutillas, Pedro
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
Cerium oxide nanoparticles (CeO NPs) possess powerful antioxidant properties, thus emerging as a potential therapeutic tool in non-alcoholic fatty liver disease (NAFLD) progression, which is characterized by a high presence of reactive oxygen species (ROS). The aim of this study was to elucidate whether CeO NPs can prevent or attenuate oxidant injury in the hepatic human cell line HepG2 and to investigate the mechanisms involved in this phenomenon. The effect of CeO NPs on cell viability and ROS scavenging was determined, the differential expression of pro-inflammatory and oxidative stress-related genes was analyzed, and a proteomic analysis was performed to assess the impact of CeO NPs on cell phosphorylation in human hepatic cells under oxidative stress conditions. CeO NPs did not modify HepG2 cell viability in basal conditions but reduced H O-and lipopolysaccharide (LPS)-induced cell death and prevented H O-induced overexpression of MPO, PTGS1 and iNOS. Phosphoproteomic analysis showed that CeO NPs reverted the H O-mediated increase in the phosphorylation of peptides related to cellular proliferation, stress response, and gene transcription regulation, and interfered with H O effects on mTOR, MAPK/ERK, CK2A1 and PKACA signaling pathways. In conclusion, CeO NPs protect HepG2 cells from cell-induced oxidative damage, reducing ROS generation and inflammatory gene expression as well as regulation of kinase-driven cell survival pathways.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bespoken Nanoceria, An Effective Treatment in Experimental Hepatocellular Carcinoma

  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Carvajal, Silvia
  • Oró, Denise
  • Casals, Eudald|||0000-0002-2900-7295
  • Boix, Loreto|||0000-0002-6015-3901
  • Oller, Laura
  • Macías-Muñoz, Laura
  • Marfà, Santi
  • Casals, Gregori|||0000-0002-3271-1371
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Casado, Pedro|||0000-0002-4207-9349
  • Rodríguez Cutillas, Pedro|||0000-0002-3426-2274
  • Bruix, Jordi|||0000-0002-9826-0753
  • Navasa, Miquel|||0000-0002-3130-9604
  • Fuster, Josep
  • García-Valdecasas, Juan Carlos
  • Pavel, Mihai C.
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeONPs) have emerged as an antioxidant agent in experimental liver disease because of their antioxidant, anti-inflammatory, and antisteatotic properties. In the present study, we aimed to elucidate the potential of CeONPs as therapeutic agents in HCC. HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeONPs at weeks 16 and 17. At the eighteenth week, nanoceria biodistribution was assessed by mass spectrometry (MS). The effect of CeONPs on tumor progression and animal survival was investigated. Hepatic tissue MS-based phosphoproteomics as well as analysis of principal lipid components were performed. The intracellular uptake of CeONPs by human ex vivo perfused livers and human hepatocytes was analyzed. Nanoceria was mainly accumulated in the liver, where it reduced macrophage infiltration and inflammatory gene expression. Nanoceria treatment increased liver apoptotic activity, while proliferation was attenuated. Phosphoproteomic analysis revealed that CeONPs affected the phosphorylation of proteins mainly related to cell adhesion and RNA splicing. CeONPs decreased phosphatidylcholine-derived arachidonic acid and reverted the HCC-induced increase of linoleic acid in several lipid components. Furthermore, CeONPs reduced serum alpha-protein levels and improved the survival of HCC rats. Nanoceria uptake by ex vivo perfused human livers and in vitro human hepatocytes was also demonstrated. These data indicate that CeONPs partially revert the cellular mechanisms involved in tumor progression and significantly increase survival in HCC rats, suggesting that they could be effective in patients with HCC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles, a new therapeutic tool in liver diseases

  • Casals, Gregori|||0000-0002-3271-1371
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Casals, Eudald|||0000-0002-2900-7295
  • Portolés, Irene
  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeONPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeONPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeONPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeONPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeONPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration

  • Ernst, Lena M.|||0000-0002-5713-7513
  • Mondragón, Laura|||0000-0002-3257-045X
  • Ramis, Joana
  • Freixanet Gustà, Muriel|||0000-0001-9872-3079
  • Yudina, Tetyana
  • Casals, Eudald|||0000-0002-2900-7295
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Casals, Gregori|||0000-0002-3271-1371
  • Jiménez, Wladimiro|||0000-0002-9376-0214
  • Puntes, Víctor|||0000-0001-8996-9499
Nanoparticle (NP) pharmacokinetics significantly differ from traditional small molecule principles. From this emerges the need to create new tools and concepts to harness their full potential and avoid unnecessary risks. Nanoparticle pharmacokinetics strongly depend on size, shape, surface functionalisation, and aggregation state, influencing their biodistribution, accumulation, transformations, and excretion profile, and hence their efficacy and safety. Today, while NP biodistribution and nanoceria biodistribution have been studied often at short times, their long-term accumulation and excretion have rarely been studied. In this work, 3 nm nanoceria at 5.7 mg/kg of body weight was intravenously administrated in a single dose to healthy mice. Biodistribution was measured in the liver, spleen, kidney, lung, brain, lymph nodes, ovary, bone marrow, urine, and faeces at different time points (1, 9, 30, and 100 days). Biodistribution and urinary and faecal excretion were also studied in rats placed in metabolic cages at shorter times. The similarity of results of different NPs in different models is shown as the heterogeneous nanoceria distribution in organs. After the expectable accumulation in the liver and spleen, the concentration of cerium decays exponentially, accounting for about a 50% excretion of cerium from the body in 100 days. Cerium ions, coming from NP dissolution, are most likely excreted via the urinary tract, and ceria nanoparticles accumulated in the liver are most likely excreted via the hepatobiliary route. In addition, nanoceria looks safe and does not damage the target organs. No weight loss or apathy was observed during the course of the experiments.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes

  • Carvajal, Silvia
  • Perramón, Meritxell
  • Casals, Gregori
  • Oró, Denise
  • Ribera, Jordi
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
Nanopartícules d’òxid de ceri; Cèl·lules hepàtiques humanes; Fosfoproteòmica, Nanopartículas de óxido de cerio; Células hepáticas humanas; Fosfoproteómica, Cerium oxide nanoparticles; Human hepatic cells; Phosphoproteomics, Cerium oxide nanoparticles (CeO2NPs) possess powerful antioxidant properties, thus emerging as a potential therapeutic tool in non-alcoholic fatty liver disease (NAFLD) progression, which is characterized by a high presence of reactive oxygen species (ROS). The aim of this study was to elucidate whether CeO2NPs can prevent or attenuate oxidant injury in the hepatic human cell line HepG2 and to investigate the mechanisms involved in this phenomenon. The effect of CeO2NPs on cell viability and ROS scavenging was determined, the differential expression of pro-inflammatory and oxidative stress-related genes was analyzed, and a proteomic analysis was performed to assess the impact of CeO2NPs on cell phosphorylation in human hepatic cells under oxidative stress conditions. CeO2NPs did not modify HepG2 cell viability in basal conditions but reduced H2O2- and lipopolysaccharide (LPS)-induced cell death and prevented H2O2-induced overexpression of MPO, PTGS1 and iNOS. Phosphoproteomic analysis showed that CeO2NPs reverted the H2O2-mediated increase in the phosphorylation of peptides related to cellular proliferation, stress response, and gene transcription regulation, and interfered with H2O2 effects on mTOR, MAPK/ERK, CK2A1 and PKACA signaling pathways. In conclusion, CeO2NPs protect HepG2 cells from cell-induced oxidative damage, reducing ROS generation and inflammatory gene expression as well as regulation of kinase-driven cell survival pathways., This research was funded by grants to W. Jiménez from Ministerio de Economia y Competitividad [grants, SAF2015-64126-R, RTI2018-094734-B-C21], to M. Morales-Ruiz [grant SAF2016-75358-R] and to G. Casals [grant PI-15/00777]; cofinanced by FEDER, European Union, a way of making Europe, Agència de Gestió d’Ajuts Universitaris i de Recerca [grant SGR 2014/219]; and Fundació La Marató de TV3 [grant Marató 120930]; Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 and Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to Eudald Casals The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases

  • Casals, Gregori
  • Perramón, Meritxell
  • Portolés, Irene
  • Fernández-Varo, Guillermo
  • Morales-Ruiz, Manuel
  • Franco Puntes, Victor
  • Casals, Eudald
Carcinoma hepatocel·lular; Regeneració hepàtica; Nanocèria, Carcinoma hepatocelular; Regeneración hepática; Nanoceria, Hepatocellular carcinoma; Liver regeneration; Nanoceria, Oxidative stress induced by the overproduction of free radicals or reactive oxygen species (ROS) has been considered as a key pathogenic mechanism contributing to the initiation and progression of injury in liver diseases. Consequently, during the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol, and vitamins E and C have received increasing interest as potential therapeutic agents in chronic liver diseases. These substances have demonstrated their efficacy in equilibrating hepatic ROS metabolism and thereby improving liver functionality. However, many of these agents have not successfully passed the scrutiny of clinical trials for the prevention and treatment of various diseases, mainly due to their unspecificity and consequent uncontrolled side effects, since a minimal level of ROS is needed for normal functioning. Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and reactive nitrogen species (RNS) scavenger and to have multi-enzyme mimetic activity, including SOD activity (deprotionation of superoxide anion into oxygen and hydrogen peroxide), catalase activity (conversion of hydrogen peroxide into oxygen and water), and peroxidase activity (reducing hydrogen peroxide into hydroxyl radicals). Consequently, the beneficial effects of CeO2NPs treatment have been reported in many different medical fields other than hepatology, including neurology, ophthalmology, cardiology, and oncology. Unlike other antioxidants, CeO2NPs are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells. In the current article, we review the potential of CeO2NPs in several experimental models of liver disease and their safety as a therapeutic agent in humans as well., Researches referred by the authors were funded by Fundació La Marató de TV3 (grant Marató 120930), Dirección General de Investigación Científica y Técnica (SAF15-64126-R and RTI2018-094734-B-C21, PID2019-105502RB, and BES-2017-08023), Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 2017/2019), and Instituto de Salud Carlos III (FIS PI15-00077 and FIS PI19-00774) co-financed by FEDER, European Union, “A way of making Europe” and the National Natural Science Foundation of China (31950410536). The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III.